Finance

Lists
Why is IDXX up 3,43%?
Dive Deeper
IDXX:NASDAQ
IDEXX Laboratories Inc
547,18 $
+3,43%
(+18,17) 1D
547,18 $
0,00% (0,00)
After hours
Closed: 15 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IDXX...
Open
538,34 $
High
547,83 $
Low
535,28 $
Mkt. cap
43,11 млрд
Avg. vol.
520,89 м.
Volume
545,29 м.
P/E ratio
38,46
52-wk high
769,98 $
52-wk low
500,61 $
EPS
14,23 $
Beta
1,55
Shares outstanding
78,78 млн
No. of employees
11 мың
Open
538,34 $
High
547,83 $
Low
535,28 $
Mkt. cap
43,11 млрд
Avg. vol.
520,89 м.
Volume
545,29 м.
P/E ratio
38,46
52-wk high
769,98 $
52-wk low
500,61 $
EPS
14,23 $
Beta
1,55
Shares outstanding
78,78 млн
No. of employees
11 мың
News stories
From web sources and news partners
Profile
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions. In 2002, Jon Ayers succeeded company founder Shaw as chairman and CEO. During Ayers 20-year tenure, the company's annual revenue grew from $380 million to $3 billion, raising share prices by more than 100 times. In 2019, Jay Mazelsky succeeded Ayers in the role of CEO. In 2025, IDEXX estimated annual sales between $4.21 billion and $4.28 billion, with total quarterly revenue exceeding $1 billion. Wikipedia
About IDEXX Laboratories Inc
CEOJay Mazelsky
Employees11 мың
Founded1983 ж. 19 жел.
HeadquartersВэстбрук, Мэн, Америка Құрама Штаттары
SectorMedical device
Websiteidexx.com
Analyst ratings
Based on 8 analysts giving stock ratings to IDXX in the past 3 months
Buy
Buy
4
Hold
4
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for IDXX in the last 3 months.
Highest
Current 547,18 $
805,00 $ (+47,12%)
Average
699,17 $ (+27,78%)
Lowest
665,00 $ (+21,53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Scott Schoenhaus
KeyBanc
Hold
Initiated
-
-
10/12/2026
Steve Dechert
KeyBanc
Hold
Initiated
-
-
10/12/2026
Ryan Daniels
William Blair
Buy
Maintained
-
-
10/02/2026
Andrea Alfonso
UBS
Hold
Reiterated
670,00 $
+22,4%
09/16/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
665,00 $
+21,5%
08/14/2026
Jonathan Block
Stifel Nicolaus
Buy
Reiterated
675,00 $
+23,4%
08/14/2026
Glen Santangelo
Barclays
Buy
Maintained
710,00 $
+29,8%
08/11/2026
Erin Wright
Morgan Stanley
Buy
Maintained
805,00 $
+47,1%
08/05/2026
Daniel Grosslight
Citi
Hold
Maintained
670,00 $
+22,4%
08/05/2026
Keith Devas
Jefferies
Buy
Reiterated
792,00 $
+44,7%
05/06/2026
Unknown Analyst
Jefferies
Buy
Reiterated
729,00 $
+33,2%
05/06/2026
David Westenberg
Piper Sandler
Hold
Maintained
750,00 $
+37,1%
02/09/2026
Mark Massaro
BTIG
Buy
Reiterated
800,00 $
+46,2%
02/03/2026
Last report
2026 ж. 04 там.
Fiscal period
Q2 2026
4,27 $ / 3,93 $
+8,54%beat
Revenue / Est. (USD)
1,22 млрд / 1,20 млрд
+1,35%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
1,11 млрд
1,09 млрд
1,14 млрд
1,22 млрд
Cost of goods sold
421,88 млн
432,46 млн
418,08 млн
437,50 млн
Cost of revenue
421,88 млн
432,46 млн
418,08 млн
437,50 млн
Research and development expenses
63,42 млн
66,83 млн
65,79 млн
65,43 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
265,09 млн
266,68 млн
294,36 млн
288,09 млн
Operating expense
328,51 млн
333,51 млн
360,15 млн
353,52 млн
Total operating expenses
750,39 млн
765,97 млн
778,23 млн
791,02 млн
Operating income
354,85 млн
324,60 млн
362,59 млн
425,57 млн
Other non operating income
-
-
-
-
EBT including unusual items
344,77 млн
306,98 млн
355,44 млн
417,22 млн
EBT excluding unusual items
344,77 млн
315,98 млн
355,44 млн
415,99 млн
Income tax expense
70,16 млн
58,79 млн
77,00 млн
78,81 млн
Effective tax rate
20,35%
19,15%
21,66%
18,89%
Other operating expenses
-
-
-
-
Net income
274,61 млн
248,19 млн
278,45 млн
338,41 млн
Net profit margin
24,85%
22,76%
24,41%
27,82%
Earnings per share
3,40
3,08
3,47
4,27
Interest and investment income
580,00 м.
587,00 м.
597,00 м.
606,00 м.
Interest expense
-10,66 млн
-9,21 млн
-7,74 млн
-10,18 млн
Net interest expenses
-10,08 млн
-8,62 млн
-7,14 млн
-9,58 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
391,47 млн
363,33 млн
400,27 млн
466,62 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары